Glaxosmithkline Research & Development Limited

• Efficacy and Safety Comparison of Niraparib to Placebo in Participants with HER2 Negative BRCAmut or Triple-Negative Breast Cancer with Mole… Ended
  2023-504454-35-00 Phase III 4 countries NIRAPARIB TOSILATE MONOHYDRATE
• Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced NSCLC… Ended
  2023-507475-21-00 Phase II/III 11 countries COBOLIMAB; DOCETAXEL; DOSTARLIMAB
• A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dex… Ended
  2023-506877-37-00 Phase III 7 countries BELANTAMAB MAFODOTIN; BORTEZOMIB; DEXAMETHASONE; DEXAMETHASONE PH. EUR.; POMALID…
• A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multipl… Ended
  2023-508962-14-00 Phase III 10 countries BELANTAMAB MAFODOTIN; DEXAMETHASONE; DEXAMETHASONE PH. EUR.; POMALIDOMIDE
• Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed… Ended
  2023-510537-28-00 Phase III 9 countries BELANTAMAB MAFODOTIN; BORTEZOMIB; DARATUMUMAB; DEXAMETHASONE; DEXAMETHASONE PH. …
• A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9) Ended
  2023-507060-39-00 Phase I (Other) 5 countries
• Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with RRMM. Ended
  2023-509550-55-00 Phase I (FiH) 4 countries BELANTAMAB MAFODOTIN; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; FELADILIMAB…
• Extended Access of Momelotinib for Subjects with Myelofibrosis Ended
  2023-508018-41-00 Phase II 10 countries MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE
• A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4… Halted
  2025-525073-37-00 Phase I (Other) 1 country
• A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants w… Halted
  2024-516095-15-00 Phase I 5 countries
• GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended
  2025-521107-42-00 Phase II 8 countries GSK4527226
• Phase 1/2 Study of Cobolimab plus Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors Ended
  2024-511350-41-00 Phase I/II 6 countries COBOLIMAB; DOSTARLIMAB
• Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection Ended
  2023-509684-24-00 Phase I (FiH) 2 countries BEPIROVIRSEN; GSK3965193B
• Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat… Ended
  2023-508474-29-00 Phase II 8 countries HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST INTERLEUKIN 18
• Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF) Ended
  2023-509371-16-00 Phase II 6 countries GSK3915393
• A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-1… Ended
  2023-509001-76-00 Phase III 5 countries SALBUTAMOL SULFATE
• A study to compare the pharmacokinetics of salbutamol administered via metered dose inhalers containing propellants HFA-152a (test) or HFA-1… Ended
  2023-508279-36-00 Phase I (Other) 1 country
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 Phase II 8 countries FLORBETABEN (18F); FLORBETAPIR (18F); FLORQUINITAU (18F); FLUTEMETAMOL (18F); GS…
• A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet… Ended
  2023-505414-15-00 Phase II 8 countries HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST INTERLEUKIN 18
• A study to investigate the pharmacokinetics of a combined oral contraceptive when given alone and in combination with GSK3036656 in female p… Ended
  2023-507839-38-00 Phase I (Other) 1 country
• A Phase 2 study (NEPTUNE-17) to evaluate efficacy and safety of GSK3858279 in DPNP. Ended
  2022-502313-28-00 Phase II 4 countries GSK3858279
• A Ph2 dose-finding study (MARS-17) to evaluate the efficacy and safety of GSK3858279 in adults with knee osteoarthritis pain. Ended
  2022-502799-22-00 Phase II 3 countries GSK3858279
• Phase 2b Study of GSK4532990 in Adults with NASH (HORIZON) Ended
  2023-507503-62-00 Phase II 5 countries GSK4532990A
• Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 2) Ended
  2023-504238-23-00 Phase III 9 countries BEPIROVIRSEN

Showing 49–72 of 89 trials